Silence Therapeutics Statistics
Total Valuation
SLN has a market cap or net worth of $327.33 million. The enterprise value is $257.39 million.
| Market Cap | 327.33M |
| Enterprise Value | 257.39M |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SLN has 47.23 million shares outstanding. The number of shares has increased by 0.35% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 47.23M |
| Shares Change (YoY) | +0.35% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 34.66% |
| Owned by Institutions (%) | 30.49% |
| Float | 24.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 390.14 |
| Forward PS | 51.50 |
| PB Ratio | 6.63 |
| P/TBV Ratio | 8.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 306.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.83, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.83 |
| Quick Ratio | 8.82 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -92.56% and return on invested capital (ROIC) is -55.14%.
| Return on Equity (ROE) | -92.56% |
| Return on Assets (ROA) | -29.79% |
| Return on Invested Capital (ROIC) | -55.14% |
| Return on Capital Employed (ROCE) | -68.42% |
| Weighted Average Cost of Capital (WACC) | 12.41% |
| Revenue Per Employee | $9,534 |
| Profits Per Employee | -$852,716 |
| Employee Count | 88 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, SLN has paid $11,000 in taxes.
| Income Tax | 11,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +29.05% in the last 52 weeks. The beta is 1.48, so SLN's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | +29.05% |
| 50-Day Moving Average | 6.83 |
| 200-Day Moving Average | 6.09 |
| Relative Strength Index (RSI) | 54.74 |
| Average Volume (20 Days) | 244,721 |
Short Selling Information
The latest short interest is 2.06 million, so 5.76% of the outstanding shares have been sold short.
| Short Interest | 2.06M |
| Short Previous Month | 1.99M |
| Short % of Shares Out | 5.76% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 9.62 |
Income Statement
In the last 12 months, SLN had revenue of $839,000 and -$75.04 million in losses. Loss per share was -$1.59.
| Revenue | 839,000 |
| Gross Profit | 667,000 |
| Operating Income | -71.61M |
| Pretax Income | -75.03M |
| Net Income | -75.04M |
| EBITDA | -71.08M |
| EBIT | -71.61M |
| Loss Per Share | -$1.59 |
Balance Sheet
The company has $70.08 million in cash and $136,000 in debt, with a net cash position of $69.94 million or $1.48 per share.
| Cash & Cash Equivalents | 70.08M |
| Total Debt | 136,000 |
| Net Cash | 69.94M |
| Net Cash Per Share | $1.48 |
| Equity (Book Value) | 49.40M |
| Book Value Per Share | 1.05 |
| Working Capital | 92.39M |
Cash Flow
In the last 12 months, operating cash flow was -$65.57 million and capital expenditures -$51,000, giving a free cash flow of -$65.62 million.
| Operating Cash Flow | -65.57M |
| Capital Expenditures | -51,000 |
| Depreciation & Amortization | 523,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -65.62M |
| FCF Per Share | -$1.39 |
Margins
| Gross Margin | 79.50% |
| Operating Margin | -8,534.68% |
| Pretax Margin | -8,942.55% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.35% |
| Shareholder Yield | -0.35% |
| Earnings Yield | -22.92% |
| FCF Yield | -20.05% |
Analyst Forecast
The average price target for SLN is $31.20, which is 350.22% higher than the current price. The consensus rating is "Buy".
| Price Target | $31.20 |
| Price Target Difference | 350.22% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 198.94% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SLN has an Altman Z-Score of -5.76 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.76 |
| Piotroski F-Score | 3 |